Isatuximab: A Review of Its Use in Multiple Myeloma.

Target Oncol · 2021 · PMC8497289 · PMID 34351561

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

OS data are immature in both ICARIA-MM and IKEMA, although there was a strong trend towards improvement with the addition of isatuximab in the former study, which is the more advanced of the two (Sect. 4 ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.